Abstracts tagged "dermatomyositis"

Abstract Number: 1848 • ACR Convergence 2022
Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope
Josh Dan¹, Grant Sprow², Josef Concha³, Nilesh Kodali⁴, DeAnna Diaz⁵, Felix Chin⁶, Thomas Vazquez⁷ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Albert Einstein College of Medicine, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴New Jersey Medical School, Coppell, TX, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁷FIU Wertheim College of Medicine, Virginia Beach, VA
Background/Purpose: Nailfold capillary (NC) abnormalities are increasingly utilized in the evaluation of rheumatic conditions. Their presence can distinguish primary Raynaud's phenomenon from secondary etiologies and…
Abstract Number: 2241 • ACR Convergence 2022
Autoantibodies and Damage in Patients with Idiopathic Inflammatory Myopathies: A Longitudinal Multicenter Study from the EuroMyositis International Network
Fabricio Espinosa-Ortega¹, Karin Lodin², Marie Holmqvist¹, Maryam Dastmalchi³, Angela Ceribelli⁴, Jiri Venkovsky⁵, Hector Chinoy⁶, Louise Diederichsen⁷, Samuel Shinjo⁸, Ingrid Lundberg⁹ and Helene Alexanderson¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska University hospital, Huddinge, Sweden, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, ⁵Charles Univ Prague, Inst Rheumatol, Prague, Czech Republic, Prague, Czech Republic, ⁶The University of Manchester, Sale, United Kingdom, ⁷Copenhagen University Hospital, Rigshospitalet, Dragør, Denmark, ⁸Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ⁹Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) may harbor autoantibodies that are associated with well-defined clinical phenotypes. The association of these autoantibodies with level of…
Abstract Number: 0699 • ACR Convergence 2021
Clinical Characteristics of Idiopathic Inflammatory Myositis Manifesting with Myoglobinuria: A 15 Year Retrospective Review
Lilian Vilar, William Moore and Ian Ward, Dwight D Eisenhower Army Medical Center, Fort Gordon
Background/Purpose: The Idiopathic Inflammatory myopathies (IIM) are characterized by muscle damage and progressive weakness. Myoglobin is not typically released in high levels in IIM and…
Abstract Number: 1007 • ACR Convergence 2021
Vascular Deposition of Oxidized LDL Is Increased in Children with Untreated Juvenile Dermatomyositis
Jacob Spitznagle¹, Akadia Kacha-Ochana², Joan Cook-Mills³, Amer Khojah², Gabrielle Morgan⁴ and Lauren Pachman⁵, ¹Hospital for Special Surgery, New York, NY, ²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Indiana University School of Medicine, Departments of Pediatrics and Microbiology & Immunology, Indianapolis, IN, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic vasculopathy associated with metabolic derangements and possible increased risk for premature atherosclerosis. Oxidation of low-density lipoprotein (LDL) in…
Abstract Number: 0700 • ACR Convergence 2021
Clinical Outcomes in Idiopathic Inflammatory Myositis Within the Military Health System: A 15 Year Retrospective Review
David Mecham¹, William Moore¹ and Ian Ward², ¹Dwight D Eisenhower Army Medical Center, Fort Gordon, ²United States Army, Evans, GA
Background/Purpose: The Idiopathic Inflammatory Myopathies (IIM) are often difficult to treat, require chronic steroid therapy, and can remain active despite multiple treatment regimens. The objective…
Abstract Number: 1026 • ACR Convergence 2021
Factors Impacting Likelihood of Discontinuing Immunosuppression in Adult Dermatomyositis: A Single-Center Study
Sung Kyung Cho¹, Lorinda Chung² and David Fiorentino³, ¹University of Texas Southwestern, Dallas, TX, ²Stanford University, Palo Alto, CA, ³Stanford University, Redwood City, CA
Background/Purpose: Dermatomyositis (DM) is a chronic idiopathic inflammatory myopathy with variable clinical course, but little is known regarding factors associated with remission of disease. We…
Abstract Number: 0701 • ACR Convergence 2021
Use and Yield of Computed Tomography as a Cancer Surveillance Method in Idiopathic Inflammatory Myositis
Christopher Mecoli¹, Brant Chee², XingYao Wang³, Mengkun Chen⁴, William Kelly³, Elizabeth Platz⁴, Livia Casciola-Rosen⁵, Lisa Christopher-Stine³ and Ami Shah⁶, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Applied Physics Laboratory, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins School of Public Health, Baltimore, MD, ⁵Johns Hopkins, Baltimore, MD, ⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: To inform guidance for cancer surveillance in patients with idiopathic inflammatory myositis (IIM), we conducted a retrospective cohort study in a single tertiary referral…
Abstract Number: 1031 • ACR Convergence 2021
Clinical and Humanistic Burden of Dermatomyositis and Polymyositis in the United States: A Systematic Literature Review
Swamy Venuturupalli¹, Namita Goyal², Nathalie Fortune³, Richard Leff⁴, Konrad Pisarczyk⁵, Izabela Aleksanderek⁶, Kiruthi Palaniswamy⁷ and Noreen Henig⁸, ¹Cedars-Sinai Medical Center, Beverly Hills, CA, ²University of California Irvine, Irvine, CA, ³Attune Health, Beverly Hills, CA, ⁴Richard L Leff MD LLC, Chadds Ford, PA, ⁵Maple Health Group, Krakow, Poland, ⁶Maple Health Group, Toronto, ON, Canada, ⁷Kezar Life Sciences, Los Angeles, CA, ⁸Kezar Life Sciences, Inc, Foster City, CA
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare heterogenous systemic autoimmune disorders of the skin, muscles, and other organs that may have a devastating impact…
Abstract Number: 0702 • ACR Convergence 2021
Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing
Sarvar Nazir¹, Lisa Rider², Ira Targoff³, Stanley Naides⁴, Andrew Mammen⁵, Steven Greenberg⁶ and Adam Schiffenbauer⁵, ¹NIEHS, NIH, Bethesda, MD, ²NIEHS, NIH, Garrett Park, MD, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Self, Dana Point, CA, ⁵National Institutes of Health, Bethesda, MD, ⁶Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions. The presence of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) in patients…
Abstract Number: 1039 • ACR Convergence 2021
Healthcare Resource Utilization and Costs of Dermatomyositis and Polymyositis in the United States: A Systematic Literature Review
Rohit Aggarwal¹, Kelly Gwathmey², Richard Leff³, Konrad Pisarczyk⁴, Izabela Aleksanderek⁵, Kiruthi Palaniswamy⁶ and Noreen Henig⁷, ¹University of Pittsburgh, Pittsburgh, PA, ²Virginia Commonwealth University Health system, Richmond, VA, ³Richard L Leff MD LLC, Chadds Ford, PA, ⁴Maple Health Group, Krakow, Poland, ⁵Maple Health Group, Toronto, ON, Canada, ⁶Kezar Life Sciences, Los Angeles, CA, ⁷Kezar Life Sciences, Inc, Foster City, CA
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare heterogenous systemic autoimmune disorders with primary target of muscle, skin, but can also impact multiple other organs.…
Abstract Number: 0705 • ACR Convergence 2021
Mitochondrial Calcification-Induced Inflammation in Human Skeletal Muscle and Immune Cells
Bhargavi Duvvuri¹, Lauren Pachman², TING WANG¹, Payton Hermanson¹ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Children with juvenile dermatomyositis (JDM) have decreased autophagy, as also confirmed by our RNA seq data in JDM muscle, which may contribute to accumulation…
Abstract Number: 1178 • ACR Convergence 2021
Implementation of a Dermatologic Manifestations of Connective Tissue Disease Learning Module Including All Skin Tones and Social Determinants of Health for Medical Students: A Pilot Study
Mavra Masood, Fnu Nutan, Julia Nunley and Beth Rubinstein, Virginia Commonwealth University, Richmond, VA
Background/Purpose: There is a dearth of resources for medical students on identifying skin findings of autoimmune disorders in skin of color. Considering how several rheumatologic…
Abstract Number: 0706 • ACR Convergence 2021
Mycophenolate Mofetil and Methotrexate Efficacy in Dermatomyositis
Madison Grinnell¹, Emily Keyes², DeAnna Diaz², Thomas Vazquez³, Rui Feng⁴ and Victoria Werth², ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ³FIU Wertheim College of Medicine, Virginia Beach, VA, ⁴University of Pennsylvania Department of Biostatistics, Philadelphia, PA
Background/Purpose: Treatment of dermatomyositis (DM) typically follows a stepwise sequence starting with either methotrexate (MTX) or mycophenolate mofetil (MMF) after an inadequate response to antimalarial…
Abstract Number: 1385 • ACR Convergence 2021
Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study
Jason Melehani¹, Shufeng Li², Joshua Mooney³ and Lorinda Chung², ¹Stanford University, San Jose, CA, ²Stanford University, Palo Alto, CA, ³Stanford University, Stanford, CA
Background/Purpose: Lung manifestations of systemic autoimmune diseases are a frequent cause of early death. For many patients, current treatments cannot arrest the inexorable progression to…
Abstract Number: 0707 • ACR Convergence 2021
Association of Pneumomediastinum with Poor Prognosis in Patients with Myositis-Associated Interstitial Lung Disease
Kazuki Hirano¹, Azusa Kojima¹, Akira Ishii¹, Mai Sugiyama¹, Yuto Izumi¹, Noriko Sasaki², Yuji Hosono¹, Chiho Yamada¹ and Shinji Sato³, ¹Tokai University School of Medicine, Isehara, Japan, ²tokai university, sagamihara-city, Japan, ³Tokai University, Isehara, Japan
Background/Purpose: Pneumomediastinum is an important complication in patients with myositis-associated interstitial lung disease (ILD). Patients with myositis and ILD who had pneumomediastinum during the disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].